Detection of PI3K inhibition in human neuroblastoma using multiplex Luminex bead immunoassay: A targeted approach for pathway analysis

Journal of Biomolecular Screening

Volumn 19, Issue 9, 2014, Pages 1235-1245

  Lang, Walter H ^a   Sandoval, John A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

IGF 1R AKT PI3k mTOR pathway; intracellular signaling screening; multiplex bead technology; neuroblastoma; PI3K inhibition

Indexed keywords

BUPARLISIB; DACTOLISIB; EVEROLIMUS; LINSITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEOME; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IMMUNOASSAY; IMMUNOASSAY ANALYZER; INTRACELLULAR SIGNALING; MULTIPLEX LUMINEX BEAD IMMUNOASSAY; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PROTEOMICS; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PHOSPHORYLATION; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; IMMUNOASSAY; NEUROBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84908874685     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114545650     Document Type: Article

References (28)

1. Young J. L., Ries L. G., Silverberg, et al. Cancer Incidence, Survival, and Mortality for Children Younger Than Age 15 Years. Cancer. 1986 ; 58: 598-602
2. Davidoff A. M.. Neuroblastoma. Semin. Pediatr. Surg. 2012 ; 21: 2-14
3. Opel D., Poremba C., Simon T., et al. Activation of Akt Predicts Poor Outcome in Neuroblastoma. Cancer Res. 2007 ; 67: 735-745
4. Segerstrom L., Baryawno N., Sveinbjornsson B., et al. I. Effects of Small Molecule Inhibitors of PI3K/Akt/mTOR Signaling on Neuroblastoma Growth In Vitro and In Vivo. Int. J. Cancer. 2011 ; 129: 2958-2965
5. Chanthery Y. H., Gustafson W. C., Itsara M., et al. Paracrine Signaling through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma. Sci. Transl. Med. 2012 ; 4:
6. Pantuck A. J., Seligson D. B., Klatte T., et al. Prognostic Relevance of the mTOR Pathway in Renal Cell Carcinoma: Implications for Molecular Patient Selection for Targeted Therapy. Cancer. 2007 ; 109: 2257-2267
7. Delbaldo C., Albert S., Dreyer C., et al. Predictive Biomarkers for the Activity of Mammalian Target of Rapamycin (mTOR) Inhibitors. Target Oncol. 2011 ; 6: 119-124
8. Bertotti A., Burbridge M. F., Gastaldi S., et al. Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Sci. Signal 2. 2009 ;:
9. Liu Y., Xu Z. Q., Zhang Q. J., et al. Simultaneous Detection of Seven Enteric Viruses Associated with Acute Gastroenteritis by a Multiplexed Luminex-Based Assay. J. Clin. Microbiol. 2012 ; 50: 2384-2389
10. Balada-Llasat J. M., LaRue H., Kamboj K., et al. Detection of Yeasts in Blood Cultures by the Luminex xTAG Fungal Assay. J. Clin. Microbiol. 2012 ; 50: 492-494
11. Kang J. H., Vanderstichele H., Trojanowski J. Q., et al. Simultaneous Analysis of Cerebrospinal Fluid Biomarkers Using Microsphere-Based xMAP Multiplex Technology for Early Detection of Alzheimer's Disease. Methods. 2012 ; 56: 484-493
12. Teitz T., Wei T., Valentine M. B., et al. Caspase 8 Is Deleted or Silenced Preferentially in Childhood Neuroblastomas with Amplification of MYCN. Nat. Med. 2000 ; 6: 529-535
13. Thiele C. Human Cell Culture. Masters J., ed. Kluwer Academic Publishers: Lancaster, UK ; 1998: 21-53.
14. Manning B. D., Cantley L. C.. AKT/PKB Signaling: Navigating Downstream. Cell. 2007 ; 129: 1261-1274
15. Kovacina K. S., Park G. Y., Bae S. S., et al. Identification of a Proline-Rich Akt Substrate as a 14-3-3 Binding Partner. J. Biol. Chem. 2003 ; 278: 10189-10194
16. Cohen P., Frame S.. The Renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001 ; 2: 769-776
17. Proud C. G.. p70 S6 Kinase: An Enigma with Variations. Trends Biochem. Sci. 1996 ; 21: 181-185
18. Zoncu R., Efeyan A., Sabatini D. M.. mTOR: From Growth Signal Integration to Cancer, Diabetes and Ageing. Nat. Rev. Mol. Cell Biol. 2011 ; 12: 21-35
19. Bliss C.. The Toxicity of Poisons Applied Jointly. Ann. Appl. Biol. 1939 ; 26: 585-615
20. Wu D., Pan W.. GSK3: A Multifaceted Kinase in Wnt Signaling. Trends Biochem. Sci. 2010 ; 35: 161-168
21. Kellar K. L., Kalwar R. R., Dubois K. A., et al. Multiplexed Fluorescent Bead-Based Immunoassays for Quantitation of Human Cytokines in Serum and Culture Supernatants. Cytometry. 2001 ; 45: 27-36
22. de Jager W., te Velthuis H., Prakken B. J., et al. Simultaneous Detection of 15 Human Cytokines in a Single Sample of Stimulated Peripheral Blood Mononuclear Cells. Clin. Diagn. Lab Immunol. 2003 ; 10: 133-139
23. Linkov F., Lisovich A., Yurkovetsky Z., et al. Early Detection of Head and Neck Cancer: Development of a Novel Screening Tool Using Multiplexed Immunobead-Based Biomarker Profiling. Cancer Epidemiol. Biomarkers Prev. 2007 ; 16: 102-107
24. McCubrey J. A., Steelman L. S., Chappell W. H., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget. 2012 ; 3: 1068-1111
25. Blankesteijn W. M., van de Schans V. A., ter Horst P., et al. The Wnt/frizzled/GSK-3 Beta Pathway: A Novel Therapeutic Target for Cardiac Hypertrophy. Trends Pharmacol. Sci. 2008 ; 29: 175-180
26. Wander S. A., Hennessy B. T., Slingerland J. M.. Next-Generation mTOR Inhibitors in Clinical Oncology: How Pathway Complexity Informs Therapeutic Strategy. J. Clin. Invest. 2011 ; 121: 1231-1241
27. Mueller A., Bachmann E., Linnig M., et al. Selective PI3K Inhibition by BKM120 and BEZ235 Alone or in Combination with Chemotherapy in Wild-Type and Mutated Human Gastrointestinal Cancer Cell Lines. Cancer Chemother. Pharmacol. 2012 ; 69: 1601-1615
28. Fu L., Kim Y. A., Wang X., et al. Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy. Cancer Res. 2009 ; 69: 8967-8976